The Pharmacovigilance team in WHO aims to assure the safety of medicines and vaccines by ensuring reliable and timely exchange of information on safety issues, promoting pharmacovigilance activities throughout the Organization and encouraging participation in the WHO Programme for International Drug Monitoring. This text was developed in known as pharmacovigilance with an exponential turn in recent years. In the course of this growth, various terminologies and parameters have been intro - duced to enable communication and exchanges among workers in the field (3-5). The need for communication on drug safety has been further endorsed Following the publication of the CIOMS Cumulative Pharmacovigilance Glossary, an Advisory Board will be formed, including a variety of different stakeholders, and will meet periodically to review all feedback received and prepare the changes, which may include edited definitions that need to be brought in line with contemporary pharmacovigilance. Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions (Rev 4) Date for coming into effect of first version . 2 July 2012 : Date for coming into effect of Revision 1 ; 13 December 2012 Date for coming into effect of Revision . 2 8 January 2014 : Basic terminologies used in pharmacovigilance Terminologies of adverse medication-related events, Regulatory terminologies Unit II Drug and disease classification Anatomical, therapeutic and chemical classification of drugs International classification of diseases Daily defined doses International Non-proprietary Names for drugs Download free PDF book doi.org/10.56759/simv6903 — CIOMS has published over ten reports on various topics in the field of pharmacovigilance, and this glossary compiles all the definitions within these reports. As the science and practice of pharmacovigilance have evolved over the past decades, so too have the related definitions. A relationship between one phenomenon or event (A) and another (B) in which A precedes and causes B. In pharmacovigilance; a medicine causing an adverse reaction. 9. The evaluation of the likelihood that a medicine was the causative agent of an observed adverse reaction. Causality assessment is usually made according established algorithms. 10. We intentionally excluded a part of scandals (e.g. inhibitors of cyclooxygenase types 2 because of cardiovascular adverse reactions), because they were mainly due to incorrect marketing or inappropriate information campaigns by pharmaceutical companies [].The history of Pharmacovigilance started 169 years ago, on Jan 29, 1848, when a young girl (Hannah Greener) from the north of England died pharmacovigilance system or the processes to be engaged in risk management, there is consensus among the major regulators that pharmacovigilance is necessary and important in the development and commercialization of medicinal products. Therefore it is essential in building capacity for clinical trials to understand the components, It discusses the principal terminologies used for coding medical conditions and medicines in the context of pharmacovigilance. The aim of coding is to impose order on the large number of ways in which medical conditions may be described and on the huge number of medicines to which patients may be exposed. Terms for Vaccine Pharmacovigilance Pharmacovigilance as well as the drug and vaccine regulatory authorities, vaccine industry, and other organizations and